Conditions · Pancreatic cancer
Pancreatic cancer — frontier options in Texas
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE2RECRUITING
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Zanidatamab — 28 sites
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
- TRIALPHASE1 / PHASE2RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VMD-928 100 mg Tablet · VMD-928 Tablet and Pembrolizumab (200 mg) — 15 sites
- TRIALPHASE1RECRUITING
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KST-6051 — 9 sites
- TRIALNARECRUITING
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
Computed Tomography (CT) · Questionnaire — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA — 1 site
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
CT3001 · FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) — 1 site
- TRIALPHASE1RECRUITING
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Sofe-M · bevacizumab · carboplatin — 24 sites
- TRIALPHASE1NOT_YET_RECRUITING
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
CLSP-5282 — 4 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
BMS-986523 · Gemcitabine · Nab-Paclitaxel — 8 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ersodetug — 13 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 223 sites
- TRIALPHASE1RECRUITING
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PTM-101 — 8 sites
- TRIALPHASE1RECRUITING
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PT0511 · Cetuximab — 9 sites
- TRIALPHASE1NOT_YET_RECRUITING
IKS04 Regimen in Advanced Solid Tumors That Express CA242
IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
A 2-part Phase 1/2 Open-label Trial on ODM-212
ODM-212 · Ipilimumab and nivolumab · Gemcitabine and nab-paclitaxel — 2 sites
- TRIALPHASE2 / PHASE3RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib · Everolimus — 126 sites
- TRIALPHASE2RECRUITING
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
Neoadjuvant Chemotherapy (NAC) · Immunotherapy (pembrolizumab) · Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) — 1 site
- TRIALPHASE1RECRUITING
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
DR-0202 — 10 sites
- TRIALPHASE1RECRUITING
A Study of MGC026 in Participants With Advanced Solid Tumors
MGC026 Dose Escalation · MGC026 Dose for Expansion — 12 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Telisotuzumab adizutecan · Fluorouracil · Folinic acid/ Leucovorina — 19 sites
- TRIALPHASE1RECRUITING
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
M0324 · M0324 · Pembrolizumab — 5 sites
- TRIALPHASE1 / PHASE2RECRUITING
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Spevatamig (PT886) · Paclitaxel · Gemcitabine — 11 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
TSN1611 · TSN1611 · TSN1611 — 19 sites
- TRIALPHASE1RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RMC-9805 · RMC-6236 — 17 sites
- TRIALPHASE1 / PHASE2RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Biospecimen Collection · Dual X-ray Absorptiometry · Tegavivint — 21 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.